AstraZeneca Links With Alibaba And Tencent In China 'Digital Health' Push
AstraZeneca agreed two new deals with Chinese tech groups Alibaba and Tencent as it tries to expand business in modernizing China, now the UK drug maker's second-largest market after the US.
You may also be interested in...
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Pascal Soriot says AstraZeneca remains on track to hit its $45bn sales target in 2023 – more or less - but to do that the UK's second biggest drug maker must maintain recent improvements in R&D productivity.
As head of AstraZeneca's global research and early development arms Menelas Pangalos has, in the space of eight years, boosted AstraZeneca's pipeline productivity from below industry average to one of the best, at a fraction of the cost. He talked to Scrip about how he effected this transformation using his "5R" framework, and what he needs to do next.